Drug profile · INN
vosoritide
VOXZOGO
vosoritide (VOXZOGO) is a atrial natriuretic peptide receptor b binding agent. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — vosoritide
- US status
- approved
- Class
- Musculo-skeletal system (M05)
- Route
- SUBCUTANEOUS
- Patents
- 6
- Programs
- 12
- Data quality
- 0.89
Quick answer
vosoritide (VOXZOGO) is a atrial natriuretic peptide receptor b binding agent. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Atrial natriuretic peptide receptor B binding agent
Primary target: Atrial natriuretic peptide receptor 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
This Week’s Biopharma News: New Approvals, Appeals, and AI
This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.
BioMarin's Strategic Move: Voxzogo Label Expansion Insights
BioMarin Pharmaceutical aims to expand Voxzogo's label following a successful trial. This article analyzes the competitive implications for pharma teams.
BioMarin Seeks Approval for Voxzogo in Short Stature Indication
BioMarin Pharmaceutical is pursuing further approval for Voxzogo to treat short stature. This article explores the implications for investors and pharma teams.
Pipeline programs
Related & competitor drugs
Related patents
-
US 12233106
C-type natriuretic peptide variants to treat skeletal dysplasia in children
granted -
US 11911446
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted -
US 11590204
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted -
US 10646550
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted -
US 9907834
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted -
US 8198242
Variants of C-type natriuretic peptide
granted
Frequently asked questions
What is vosoritide?
vosoritide (VOXZOGO) is a atrial natriuretic peptide receptor b binding agent. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for vosoritide?
VOXZOGO is a marketed brand name for vosoritide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vosoritide?
vosoritide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.